Biotech Values

[DewDiligence]

VRUS/ACHN/IDIX: …it's become pretty clear to me that their prospects are fairly bleak now. I can't imagine any scenario in which I'd ever seriously consider the stock again, regardless of how cheap it gets, just because I think they're in such bad shape now fundamentally. I don't understand how the stock is still holding up fairly well.

Agreed on all counts; however, if you’re following such HCV companies as ACHN and VRUS, which I think you are, it pays to stay abreast of what competitors are doing.

Based on IDIX’s CC today, I would say that you no longer need to be concerned about what IDIX is doing with PI’s and NS5A inhibitors; management all but acknowledged on the CC that these programs—which are still in preclinical development—are too little, too late to be of any consequence. Instead, IDIX intends to devote the resources it still has to taking on VRUS in the nuke arena.

p.s. Management said IDX375 is on the back burner, but we already knew that.